A LAparoscopic and TransAnal Total Mesorectal Excision (TME) for Rectal Cancer Trial
- Conditions
- Colorectal Neoplasm
- Registration Number
- NCT02324556
- Lead Sponsor
- Sahlgrenska University Hospital, Sweden
- Brief Summary
All patients planned for an anterior resection due to rectal cancer with a total mesorectal excision are included. This is a feasibility study, thus no randomization will be performed.
Primary endpoint is clinical and pathologic examination of the specimen. Secondary end-points include clinical variables such as conversion rate, re-admission and/or re-operation due to any complication and health economy analyses.
- Detailed Description
The design is comparative and prospective, we will compare specimens from patients operated at our institution during the last year with standard open or laparoscopic approach with patients operated with the new technique. Patients in the control arm will be patients operated prior to the commencement of the new technique or patients not eligible or possible to include in the study.
It is possible to obtain a macroscopically and microscopically adequate specimen after a combined approach with laparoscopic and transanal TME compared to open or laparoscopic conventional TME.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 6
- presenting with a rectal cancer possible to operate with a total mesorectal excision and an anastomosis according to the local multidisciplinary conference
- possible to operate with laparoscopic technique
- possible to operate in regard to concomitant disease
- giving informed consent to participate
-Participation in other trials in conflict with the protocol and end-points the LATA-trial
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of specimens with grade I specimen according to Quirke 4 weeks postoperatively Comparison with control group
- Secondary Outcome Measures
Name Time Method Postoperative complications scored according to Clavien-Dindo within the first 12 months 12 months Conversion rate day of surgery Re-admission 30 days
Trial Locations
- Locations (2)
NU-sjukvården
🇸🇪Trollhattan, Sweden
Dept. of Surgery, Sahlgrenska University Hospital/Ostra
🇸🇪Gothenburg, Sweden